2022年12月6日

RetinAI推出Discovery CORE™:一個人工智能驅動的協作平台，加速眼科臨床和學術研究，RWE分析:瑞士伯爾尼，2022年12月1日-視網膜AI醫療公司(“視網膜AI”)是開發眼科圖像處理和人工智能軟件解決方案的領導者，自豪地推出帶有人工智能的視網膜液和層分割的Discovery CORE™。Discovery CORE及其人工智能模型旨在加速數據分析，並幫助臨床和學術研究人員在醫療和成像數據集上與同行更有效地實時協作。該軟件實時自動測量OCT數據集的視網膜液量和層厚。此外，它集成了注釋工具和電子病例報告表格，能夠跨對等網絡收集新的數據見解，保持信息的數字化、集中化和安全。CORE的功能可用於大規模評估疾病終點，快速啟動登記處和真實世界證據數據集的構建，並幫助共享工作流程，以評估數據，培訓醫生，並在診所內建立最佳實踐。Discovery CORE使用RetinAI的ce標記流體和層分割AI模型，快速可視化並生成OCT體積上的流體體積和視網膜層厚度等測量值。AI模型可以在DICOM和其他廠商特定的oct格式上進行處理。使用AI模型進行流體分割，CORE測量視網膜下和視網膜內流體(SRF和IRF)的體積，以及色素上皮脫落(PED)。用於層分割的AI模型測量視網膜的總厚度以及視網膜6個單獨層的層厚，包括光感受器和視網膜色素上皮層。描述:探索核心平台和它的人工智能。 Features displayed include the overlay of AI on OCT images to visualize fluid and layers, side-by-side imaging comparisons on two different time-points or visits, and at the bottom, progression plots for retinal fluid volume of a patient over time. Free Trial RetinAI is excited to offer Discovery CORE and its AI as a free trial for the first 2 months for users signing up on the platform. Following the free trial, users can subscribe to Discovery CORE and its AI for 179 € per month per user to access fluid and layer AI models and other user-friendly features to accelerate their data analysis and collaboration across clinical and research datasets. To learn more about Discovery CORE and how to get started please visit https://www.retinai.com/products/discovery/core Launch Webinar The company is also sponsoring the first of a series of informational webinars titled, Elevate your research workflows with accelerated data analysis and improved collaboration using Discovery CORE™, presented by Prof. Dr. Marion Munk. Prof. Dr. Munk is a Retina Specialist and Senior Physician of the University of Bern Hospital and the Managing Director of the Bern Photographic Reading Center, with extensive experience in clinical and academic research. If you are interested in participating in this webinar on December 15, 2022 from 7pm-8pm CET (1pm-2pm EST), please register here . -ENDS- About RetinAI RetinAI Medical AG (RetinAI), founded in early 2017, is a Swiss company with offices in Bern and Boston, developing software solutions to accelerate clinical, research and pharmaceutical workflows globally using advanced machine learning and computer vision. The company builds tools to collect, organize and analyze health data from the eyes, enabling healthcare professionals to make the right decisions sooner in healthcare. RetinAI's international team combines clinical, technical, and scientific knowledge to foster the transition from reactive to preventive medicine for severe diseases affecting the eye. www.retinai.com For further information please contact: At the company